ORGANIC
LETTERS
2010
Vol. 12, No. 5
1116-1119
Reactions of Oxetan-3-tert-butylsulfinimine
for the Preparation of Substituted
3-Aminooxetanes
Philip J. Hamzik and Jason D. Brubaker*
Department of Chemistry, Merck and Co., Inc., 33 AVenue Louis Pasteur,
Boston, Massachusetts 02115
Received January 17, 2010
ABSTRACT
The oxetane ring is useful in drug discovery as a bioisostere for both the geminal dimethyl group and the carbonyl group. A convenient,
straightforward approach to access structurally diverse 3-aminooxetanes through the reactivity of oxetan-3-tert-butylsulfinimine and the
corresponding sulfinylaziridine is described.
The replacement of a geminal dimethyl group with an
oxetane ring is a potentially useful exercise in drug discov-
ery.1 Although presenting a similar van der Waals volume
to a geminal dimethyl group, an oxetane ring can be more
stable to oxidative metabolism and exhibit decreased lipo-
philicity, two properties that can confer an enhanced phar-
macokinetic profile.1a The decreased lipophilicity can also
mitigate undesirable off-target effects, such as hERG channel
binding2 and hPXR activation.3 Additionally, studies suggest
that an oxetane ring can also act as a stable surrogate for
the carbonyl group; both groups have similar hydrogen-bond
basicity,4 but oxetanes do not have the same electrophilic
reactivity or susceptibility toward R-epimerization of
stereocenters.1b
During the course of a medicinal chemistry program, we
became interested in preparing a 3-aryl-3-aminooxetane
(Figure 1) in order to examine the possibility of replacing
(1) (a) Wuitschik, G.; Rogers-Evans, M.; Mu¨ller, K.; Fischer, H.;
Wagner, B.; Schuler, F.; Polonchuk, L.; Carreira, E. M. Angew. Chem.,
Int. Ed. 2006, 45, 7736–7739. (b) Wuitschik, G.; Rogers-Evans, M.; Buckl,
A.; Bernasconi, M. M.; Godel, T.; Holger, F.; Wagner, B.; Parilla, I.;
Schuler, F.; Schneider, J.; Alker, A.; Schweizer, W. B.; Mu¨ller, K.; Carreira,
E. M. Angew. Chem., Int. Ed. 2008, 47, 4512–4515.
Figure 1. Oxetanes as potential bioisosteres for the geminal
dimethyl or carbonyl group.
the dimethyl group in a key pharmacophore for the reasons
outlined above. At the time, we found no reports of this
structural motif, which was surprising given the apparent low
degree of structural complexity.5
(2) (a) Fermini, B.; Fossa, A. Nat. ReV. Drug DiscoVery 2003, 2, 439–
447. (b) Jamieson, C.; Moir, E. M.; Rankovic, Z.; Wishart, G. J. Med. Chem.
2006, 49, 5030–5046.
(3) (a) Ngan, C.; Beglov, D.; Rudnitskaya, A. N.; Kozakov, D.; Waxman,
D. J.; Vajda, S. Biochemistry 2009, 48, 11572–11581. (b) Gao, Y.-D.; Olson,
S. H.; Balkovec, J. M.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E. Y.;
Tang, W.; Hartley, D. P.; Mosley, R. T. Xenobiotica 2007, 37, 124–138.
(4) (a) Berthelot, M.; Besseau, F.; Laurence, C. Eur. J. Org. Chem. 1998,
925–931. (b) Besseau, F.; Lucon, M.; Laurence, C.; Berthelot, M. J. Chem.
Soc., Perkin Trans. 2 1998, 101–107.
(5) During the preparation of this manuscript, a related report was
published in the patent literature: Rainer, A.; Cooke, N. G.; Zecri, F.; Lewis,
I. International Patent Application WO 2009/068682 A2, June 4, 2009.
10.1021/ol100119e 2010 American Chemical Society
Published on Web 02/08/2010